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87-Rubidium MMR, cation flux 1249
A6 cell RNA encoding (abst) 155
ACE inhibitors (abst) 245, 277, 332, 437
ADPKD
cell proliferation and fluid secretion in cysts 1384
cyst-derived cells in vitro 1356
DNA probe in diagnosis of (abst) 738
renal concentrating capacity 675
ADPase (abst) 359
ADR nephrosis (abst) 472
AIDS nephropathy (abst) 213, 215, 222, 234, 368
ATPases
analysis (abst) 448, 462, 502
antagonists and inhibitors (abst) . . 157, 320, 337, 431, 459,
466, 467
drug effects on (abst) 299, 314
isolation and purification (abst) 154
pathophysiology (abst) 167, 418, 489
pharmacokinetics (abst) 423
pharmacologic actions (abst) 483
physiology (abst) 157, 431, 452
regulation (abst) 161, 311, 321, 323, 337, 430, 478
transport (abst) 461, 463
Abdominal aorta, arteritis (abst) 913
Abscesses, renal and pen-renal (abst) 910
Acetates (abst) 243, 257
Acid B-galactosidases compared 1295
Acid-base
balance, Ca and KHCO3 688
disorder, CY/base exchange in mesangial cells 783
net acid excretion, "new" bicarbonate 1277
Acid-base equilibrium
drug effects on (abst) 237
drug therapy (abst) 241
pathology (abst) 458
pathophysiology (abst) 453, 454
physiology (abst) 388
regulation (abst) 172, 173, 180, 215
transport (abst) 455, 461





amino acid dialysis solution in CAPD 1189
sulfate effect after urinary diversion 105
voltage-dependent, induced by amiloride 1107
Acquired immunodeficiency syndrome
complications (abst) 212, 213, 217, 234, 339, 388
diagnosis (abst) 268
immunology (abst) 242
mortality (abst) 208, 248, 260
occurrence (abst) 258
pathology of HIV-associated nephropathy 1363
pathophysiology (abst) 484
Active transport (abst) 186, 299, 462
Acute hypersensitivity nephritis (abst) 210, 227
Acute nephritis (abst) 345
Acute poststreptococcal glomerulonephritis (abst) . 212, 216,
356, 376
Acute primary pyelonephritis, early cortical scarring. . . . 696
Acute renal failure
ANP and dopamine in ischemia 1126
CsA nephrotoxicity, uninephrectomy 1175
atraumatic rhabdomyolysis, hyperpyrexia (abst) 752
complications (abst) 404
diagnosis (abst) 393
drug effects on (abst) 315
drug therapy (abst) 282, 400, 403, 415, 477
etiology (abst) 204, 225, 227, 228, 525
interstitial nephritis 1257
metabolism (abst) 418
mortality (abst) 234, 410




prevention and control (abst) . 296, 406, 408, 414, 508, 525
rehabilitation (abst) 232
renal function in children after 84
snake-bite induced in India 891
therapy (abst) 223, 251, 292
Acute tubular necrosis
diagnosis (abst) 416
pathophysiology (abst) 403, 407, 416, 418
prevention and control (abst) 402, 415, 512
Acyl transferases (abst) 169
Adenosine
analogs and derivatives (abst) 470
antagonists and inhibitors (abst) 310, 415
biosynthesis (abst) 430
mesangial cell contraction 1300
metabolism (abst) 182, 407
pharmacologic actions (abst) . 179, 257, 309, 314, 316, 435,
471, 472
physiology (abst) 403, 474
transport (abst) 400
Adenosine triphosphate (abst) 398, 400, 442, 444, 449
Adenylate cyclase (abst) 173, 175, 298, 446, 476
Afferent arterioles
effect of prostanoids on renin release 1138
Affinity chromatography (abst) 363
Age factors (abst) 270, 280, 513, 519
Aged (abst) 262, 334
Aggregates (abst) 502
Aggrephores (abst) 187, 305
Aging (abst) 161, 176, 346
Alanine (abst) 407
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biosynthesis (abst) 431, 441
blood (abst) 406, 432
pharmacologic actions (abst) 473





renal water transport (abst) 750
Aldose reductase (abst) 292, 425, 433, 499, 501
Aldosterone
(abst) 169, 291
adverse effects (abst) 216
metabolism (abst) 299
pharmacologic actions (abst) 162, 299, 486
physiology (abst) 454, 480, 485, 486
regulation (abst) 459
secretion (abst) 279, 300, 300, 329
Alkalies (abst) 218
Allograft




superoxide dismutase (abst) 746
Alport's syndrome (abst) 203, 205
Aluminum
absorption and excretion by intestine (abst) 745
adverse effects (abst) . . . 189, 192, 265, 267, 377, 378, 378,
379
desferrioxamine therapy in HD 1376
exposure due to contaminated concentrate (abst) 753
intestinal absorption, diet 1306
micromolar levels reduce 3H-thymidine, UMR
106-01 1119
pathophysiology (abst) 380
pharmacologic actions (abst) 252, 261, 399
physiology (abst) 379
toxicity (abst) 377, 397, 398
transport (abst) 399
Aluminum hydroxide (abst) 221, 427
Amiloride
analogs and derivatives (abst) 156, 465
induced, voltage-dependent tubular acidosis 1107
pharmacologic actions (abst) 160, 288, 443, 455, 458
Amino acids
blood (abst) 192
dialysis solution in CAPD 1189
gluconeogenic, alanine and BCAA on hemodynamics
(abst) 756
metabolism (abst) 196, 437
pharmacologic actions (abst) 308
physiology (abst) 475
plasma and muscle free, CAPD 1219
supplements, none in CRF diet (abst) 737
therapeutic use (abst) 396
transport (abst) 413
Aminoglycosides (abst) 229, 406, 511
Aminonucleoside nephrosis
anionic charge in GBM 1410
Aminonucleosides (abst) 209, 420
Ammonia
biosynthesis (abst) 445, 447, 463
kinetics (abst) 398
secretion (abst) 442, 460
transport (abst) 452, 459
Ammonium chloride (abst) 173, 447
Amphotericin (abst) 409, 412, 419
Amylase (abst) 190
Amyloid
syndromes in hemodialysis 567
Amyloidosis
(abst) 212, 224
132-m related in chronic HD (abst) 744
clinical presentation (abst) 910
Analbuminemia (abst) 428, 442
Analgesic nephropathy (abst) 192
Analgesic syndrome




CRF, effects of recombinant erythropoietin 134
adverse effects (abst) 246
drug therapy (abst) . 193, 227, 229, 240, 245, 257, 265, 266,
273, 321, 334
i.p. deferoxamine therapy for iron overload in
children 1335
iron status, erythropoietin 712
therapy (abst) 196
Angiocardiography (abst) 414
Angioplasty in stenosis of AVF in HD (abst) 754
Angiotensin II
concentration of inositol phosphates 1325
pregnancy, effects on BP and Na excretion (abst) .... 750
vasoconstrictors normalize GFR in postobstruction . . 1311
Angiotensin converting enzyme
(abst) 234, 298, 482
treatment in hypertension (abst) 750
Angiotensinases (abst) 304
Angiotensins
administration and dosage (abst) 298, 301
antagonists and inhibitors (abst). . . 207, 300, 302, 303, 416
biosynthesis (abst) 325, 333
metabolism (abst) 303, 304, 443
pathophysiology (abst) 405, 474
pharmacologic actions (abst) . 158, 172, 183, 196, 279, 300,
301, 302, 304, 320, 445, 460
physiology (abst) 288, 302, 423, 440, 458, 472, 473
regulation (abst) 302, 303, 354
secretion (abst) 338
Angiotension II
receptors in IgAN (abst) 741
Anions (abst) 164, 179, 493, 495
Anisotropy microscopy. cell imaging (abst) 154
Ankylosing spondylitis (abst) 213
Antacids (abst) 261
Antagonists and inhibitors (abst) 287, 288
Anti-inflammatory agents
non-steroidal (abst) 206, 420
Antibiotics (abst) 247, 253, 511
Antibodies
adverse effects (abst) 339, 349, 351
against neutrophil cytoplasmic antigen (abst) 743
circulating immune complexes 993
collagen in the basement membrane 1195
cross reactivity of anti-DNA (abst) 746
definition of intercalated cell subtypes (abst) 150
immunopathogenesis of TIN 938
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interaction with renal cell surface antigens 954
isolation and purification (abst) 347
occurrence (abst) 255, 268
pathophysiology (abst) 373, 524
pharmacokinetics (abst) 351
physiology (abst) 352
therapeutic use (abst) 506
to CIQ antigen in MPGN 836
type III collagen localized 1203
Antibody
formation (abst) 363, 514, 520
lack of xenoantibody response, transplantation (abst) . 746
transplantation, CsA and transfusion 1057
Antidiuresis, obstructed or dehydrated kidney, P-3l
NMR 830
Antigen-antibody reactions (abst) 347, 360
Antigens
adverse effects (abst) 344, 358, 365
definition of discrete glomerular (abst) 740
expression in normal and glomerulonephritic kidney . . 116
HLA in rejection episodes (abst) 742
immunology (abst) 508
isolation and purification (abst) 340
physiology (abst) 344, 352
regulation (abst) 509
retroviral gp7O, mesangial glomerulonephritis 638
Antilipemic agents (abst) 429, 436
Antioxidant therapy
ischemic renal failure 1282
Antioxidants (abst) 421




analogs and derivatives (abst) 312
metabolism (abst) 290, 290, 293, 295, 296, 298
pharmacologic actions (abst) 296
regulation (abst) 315, 482
Arginine (abst) 474
Arginine vasopressin
reflex non-osmotic control of (abst) 755
Aromatic amino acid decarboxylases (abst) 312
Arteriolar C3 disease (abst) 750
Arteriolar nephrosclerosis (abst) 334
Arteriovenous shunt, surgical (abst) 259
Arteritis
primary, of the aorta (abst) 913
surgical management (abst) 913
Artificial membranes
adverse effects (abst) 240, 242, 248, 256, 258, 266
instrumentation (abst) 251, 260, 262
methods (abst) 239, 261, 263
physiology (abst) 249, 254, 259





Atherosclerosis (abst) 201, 239, 333, 437
Atraumatic rhabdomyolysis, ARF (abst) 752
Atrial natriuretic factor
administration and dosage (abst) 283, 286
analogs and derivatives (abst) 278, 281, 282, 283, 289
analysis (abst) 207, 278, 279
and intrarenal hormone systems, mineralocorticoids .. 767
blood (abst) 281, 283, 287, 289, 290, 405
drug effects on (abst) 229
enzymatic and binding effects 799
isolation and purification (abst) 278, 289
kinetics (abst) 279
metabolism (abst) 285, 479
pharmacologic actions (abst) . 158, 279, 280, 280, 282, 283,
284, 284, 285, 285, 286, 287,
287, 288, 288, 300, 483
physiology (abst). . . . 277, 279, 281, 284, 286, 289 408, 423
regulation (abst) 471
secretion (abst) 227, 264, 280, 282, 286, 441
split hydronephrotic kidney, autoregulation 1151
therapeutic use (abst). . . . 282, 411, 417, 420, 506, 509, 511
Atrial natriuretic factor binding proteins (abst) 278
Atrial natriuretic peptide
binding, chronic heart failure (abst) 740
dopamine in ischemic ARF 1126
effect on transport (abst) 751
natriuresis inhibited by CE! (abst) 751
volume homeostasis in NS (abst) 759
Autoantibodies
adverse effects (abst) 341, 346
biosynthesis (abst) 346, 363
immunology (abst) 208, 226, 341
isolation and purification (abst) 347
pathophysiology (abst) 211, 369, 370
Autoantigens 923
(abst) 372
Autoimmune injury (abst) . 339, 341, 342, 343, 344, 345, 347,
348, 349, 354, 355, 356,
359, 360, 362, 364, 367
Autoimmunity and the kidney 923
Autonomic nervous system
growth and development (abst) 474
pathophysiology (abst) 471, 519




prednisolone therapy in transplantation (abst) 745
Azotemia (abst) 190, 435
B cell lymphoma (abst) 510
B cells (abst) 347, 407, 526
Band 3 proteins (abst) 150, 152, 159, 463
Bartter's syndrome (abst) 207, 216
Basement membrane
analysis (abst) 163








cytochalasin B binding 1290
Benzoates (abst) 398
Beta adrenergic blockers (abst) 238
Beta-2-microglobulin
(abst) 238, 259, 263, 265
adverse effects (abst) 241
kinetics (abst) 252
metabolism (abst) 258




adverse effects (abst) 463
drug effects on (abst) 452
"new" in net acid excretion 1277
regulation (abst) 156, 444
secretion (abst) 456, 457, 461, 462
therapeutic use (abst) 241, 249, 263, 271
transport (abst) . . .. 306, 384, 451, 452, 453, 454, 455, 456,
458, 459, 460, 460, 464, 465
Bile acids and salts (abst) 382
Binding sites
analysis (abst) 316, 319




Biofllms (abst) 247, 271, 275
Bioimpedance (abst) 239
Biological membranes, polycations and MCN (abst) . . . . 760
Biopsy
(abst) 513, 521, 526
improved technique (abst) 745




ultrastructure (abst) 453, 456, 461
Bleeding time (abst) 235
Blood
coagulation abnormalities in Blacks with NS (abst) . . . 914
DDAVP to correct skin bleeding time (abst) 751
hemostasis activation in NS (abst) 758
pretransplant transfusion, CsA (abst) 739
Blood coagulation disorders (abst) 257, 294, 518, 525
Blood coagulation factors (abst) 198, 202, 510
Blood flow
measurement (abst) 243
thromboxane inhibition during allograft rejection 24
Blood gas analysis (abst) 214, 259
Blood groups (abst) 371, 522
Blood pressure
(abst) 324, 326, 330, 337
Na-retaining effects of mineralocorticoids 767
antihypertensive therapy 790
calcium metabolism and hypertension 717
drug effects on (abst) . . . 240, 259, 283, 288, 301, 304, 309,
311, 313, 329, 334
physiology (abst) 236, 264, 336
progression of renal insufficiency 670
relates to urinary stone disease (abst) 754
serum ionized calcium (abst) 748
split hydronephrotic kidney 1151
Blood proteins, transport (abst) 275
Blood transfusion
(abst) 250, 518, 522, 522
adverse effects (abst) 519
complications (abst) 241, 246
therapeutic use (abst) 504
Blood urea nitrogen (abst) 247, 255, 260
Body fat, CAPD (abst) 752
Body fluid compartments (abst) 237, 252, 264, 274, 494
Bombesin (abst) 318, 502
Bone
(abst) 376, 378, 378, 399
and joint disease in primary hyperoxaluria (abst) 908
development (abst) 377
disease, Al-related, desferrioxamine 1376
IgAl elevated by marrow in IGAN 1405
marrow transplantation, mesangiolysis, renal failure . 1341
vitamin D in moderate renal failure 661
Bone diseases
drug therapy (abst) 220
etiology (abst) 258, 267
pathophysiology (abst) 261, 378, 379
prevention and control of (abst) 377
Bone marrow
(abst) 245
transplantation (abst) 223. 419
Bradykinin (abst) 168, 169, 171
Brain
analysis (abst) 278, 498
dehydration after rapid correction of hyponatremia.... 69








analysis (abst) 153, 159, 388
anatomy and histology (abst) 159, 164
drug effects on (abst) 411
physiology (abst) 150, 164, 166, 168, 382
transport (abst) 161, 302, 385, 451, 452, 492
ultrastructure (abst) 166, 501
Brush border membrane
glucose metabolism (abst) 152
light chain binding sites (abst) ISO
phosphate depletion alters phospholipid (abst) 153
Bumetanide (abst) 337, 452
Burst forming unit erythroid (abst) 755
Butyrate (abst) 500
C3 disease, arteriolar (abst) 750
C3 nephritic factor (abst) 372
CAPD
amino acid dialysis solution 1189
analysis (abst) 274
body fat status (abst) 752
complications (abst). 267, 268, 268, 269, 271, 272, 275, 342
drug therapy (abst) 273
induction of IL-I during 1212
loss of peritoneal membrane function (abst) 908
methods (abst) 268
pathophysiology (abst) 270, 271, 378
peritonal morphology (abst) 740
peritonitis (abst) 744
peritonitis spread by biofllm along catheter surface . . . 614
persistent peritonitis, treatment 908
PTFE wheel catheter (abst) 908
pharmacokinetics (abst) 277
physiology (abst) 271
plasma and muscle free amino acids 1219
rational treatment of peritonitis (abst) 913
relevance of urea kinetic modeling (abst) 744
therapeutic use (abst) 199
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total body nitrogen (abst) 742
transport of serum proteins and dextran 1064
two-pore formalism in solute transport 1234
ultrafiltration (abst) 752
CAVH, simulation with a math model 125
Cadaveric transplantation
complications (abst) 526






gene related peptide (abst) 311
pharmacologic actions (abst) 311, 315, 321, 391
physiology (abst) 391
therapeutic use (abst) 525
Calcitriol
biosynthesis (abst) 392
metabolism (abst) 390, 395, 396
physiology (abst) 391
therapeutic use (abst) 391
uremia 860
Calcium
adverse effects (abst) 404
analogs and derivatives (abst) 221, 292
and Mg homeostasis following urinary diversion 105
anionic sites of mesangial cells, poly-L-lysine 817
balance, KHCO3 improves in healthy men 688
intracellular (abst). . 156, 168, 171, 171, 175, 177, 180, 182,
279, 293, 301, 309, 314, 324, 331, 332,
337, 387, 393, 398, 438, 463, 505
metabolism (abst) 254, 338, 426
metabolism and hypertension 717
metabolism disorders (abst) 271, 395
oral load (abst) 758
pathophysiology (abst) 409
pharmacologic actions (abst) 166, 292, 474
physiology (abst) 394, 435
regulation (abst) 243, 333, 335, 386, 399, 486
secretion (abst) 378, 379
serum ionized and BP (abst) 748
stones disease, metabolic abnormalities (abst) 749
therapeutic use (abst) 377
toxicity (abst) 170
transport (abst) . . .. 169, 177, 179, 183, 183, 184, 279, 380,
381, 382, 384, 386, 387, 397, 493
urine (abst) 194
Calcium carbonate (abst) 255, 264
Calcium channel blockers (abst) 281, 282, 291
Calcium citrate (abst) 399




Calorie restriction (abst) 327
adrenergic control of generation in IMCD 647
dopamine stimulation of (abst) 153
membrane fluidity in epithelial cells (abst) 155
thrombin effect 824
Campylobacter jejuni gastroenteritis (abst) 749
Canine hereditary nephritis
NCI domain of collagen type IV in GBM 843
Captopril
diagnostic use (abst) 302, 331, 335
pharmacologic actions (abst) 211, 287, 326, 327, 334
therapeutic use (abst) 197, 199, 336, 422
Carbicarb (abst) 463
Carbohydrates (abst) 248, 498
Carbon dioxide (abst) 453, 454, 466
Carbonic acid (abst) 461
Carbonic anhydrase




output (abst) 331. 463
pacing, artificial (abst) 283
Carnitine (abst) 266, 267
Carrier proteins
analogs and derivatives (abst) 164




(abst) 214, 257, 267, 482
drug effects on (abst) 332
in IMCD, adrenergic control of cAMP 647





ageing of silicone rubber peritoneal (abst) 757
complications (abst) 253, 275
double-lumen, silicone rubber and permanent access. . 887
loss of peritoneal membrane function 908
methods (abst) 237, 262
peritonitis in dialysis by biofllm 614
PTFE wheel, CAPD (abst) 908
surgery (abst) 269
tissue adhesive use in implantation (abst) 757
Cation flux, 87-rubidium NMR 1249
Cationic drugs (abst) 493
cDNA (abst) 298
Cell
adhesion (abst) 156, 186, 352, 361
communication (abst) 173, 473, 508
contraction, Al-type receptor, adenosine 1300
culture techniques (abst) 167, 419
cultured (abst) 160, 343, 348, 355, 360, 362, 507
death (abst) 408
differentiation (abst) 170, 174, 186, 314
division (abst) 451
growth, hepatoma 02 conditioned medium 1245
imaging of membrane fluidity (abst) 154
line UMR 106-01, Al levels 1119
line, transformed (abst) 164. 166
lysis (abst) 525
mediated immunity in ON (abst) 741
procoagulant activity (abst) 743
proliferation and fluid secretion in cysts 1384
proliferation, gene expression in ureteral obstruction. 1320
red, cation transport in uremia, hemodialysis 595
surface antigens react to antibodies 954
Cell membrane
antibodies to (abst) 360
pathology (abst) 153
permeability (abst) 187, 188, 361
physiology (abst) 461
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ultrastructure (abst) 160, 162, 188
Cell proliferation
(abst) .. . . 173, 176, 179, 179, 184, 184, 306, 339, 357. 384,
401, 408
antagonists and inhibitors (abst) 157, 187, 277, 507
drug effects on (abst) 447
pathophysiology (abst) 178, 340
physiology (abst) 428




pathophysiology (abst) 330, 487
regulation (abst) . . . 155, 160, 184, 478, 479, 483, 487, 488,
489, 491, 500, 503
Central pontine myelinolysis (abst) 218
Cerebrovascular disorders (abst) 324
Chelating agents (abst) 265
Chemoreceptors (abst) 294
Chemotactic factors (abst) 254, 342, 361, 369
Chemotaxis (abst) 361
Children
ascending pyelonephritis and kidney growth 1133
Fanconi syndrome, urine glyceraldehyde excretion .... 99
FSGS in South Africa (abst) 914
hepatitis B nephrotic syndrome (abst) 909
i.p. deferoxamine therapy for iron overload, CAPD.. 1335
low P04, low protein diet, CRF (abst) 737
malnourished, urinary tract infection (abst) 910
post-ARF renal function in 84
renal vein thrombosis (abst) 751
transplantation and dialysis (abst) 753
Chloride
deficiency (abst) 452, 455, 464, 466
intracellular (abst) 485
physiology (abst) 454
regulation (abst) 156, 167, 478, 481, 481, 485, 486
transport (abst) . . . . 160, 176, 306, 432, 453, 454, 455, 456,
457, 476, 480, 484, 487, 491, 502
Cholesterol
(abst) 150, 239, 437, 473
embolism (abst) 228
modulates BBM fluidity and Pi transport 150
Chondroitin (abst) 352
Chromatography (abst) 168, 183, 357, 510, 514
Chromium release T cell cross match (abst) 909
Chromogranin A (abst) 332, 335
Chronic glomerulonephritis (abst) 374
Chronic heart failure
ANP binding (abst) 740
Chronic renal disease
amyloid syndromes in hemodialysis 567
hemodynamic changes vs. hypertrophy 654
Chronic renal failure
analysis (abst) 201, 228
anemia, recombinant erythropoietin 134
complications (abst) . . . . 192, 199, 235, 238, 252, 271, 396,
422, 435
diagnosis (abst) 233, 439
diet therapy (abst) 226, 424
drug therapy (abst). . 220, 220, 229, 318, 379, 384, 427, 440
etiology (abst) 223, 228, 229
immunology (abst) 198, 371, 375
intestinal absorption of Al 1306
lipid metabolism 40
metabolism (abst) 195, 390, 395, 446
mortality (abst) 523
occurrence (abst) 222, 234
outcome (abst) 190, 194, 198
pathophysiology (abst).. 197, 221, 276, 284, 285, 294, 346,
392, 394
phosphate restriction, PGE2 excretion (abst) 737
plasma and muscle free amino acids, CAPD 1219
protein restriction (abst) 909
Schistosoma mansoni, mesangiocapillary GN 1227
therapy (abst) 223
vitamin D receptors decreased in parathyroid glands. . . 19
Chylomicrons (abst) 425
Ciprofloxacin (abst) 227
Circadian rhythm (abst) 470
Circulatory failure (abst) 214
Cisapride (abst) 272
Cisplatin
(abst) 218, 383, 402, 409
nephrotoxicity (abst) 740
nephrotoxicity, PTX (abst) 755
Citrate synthase (abst) 485
Citrates (abst) 337, 378, 398, 443
Cl/base exchange in mesangial cells, pH regulation.... 783
CIQ antigen antibody in MPGN 836
Clearance
lithium in humans 1183
nephrectomy and glomerular solute transport 589
two-pore formalism, solute transport in CAPD 1234
Clindamycin (abst) 244
Cloning, molecular (abst) 155, 163, 358
Co-transport
analysis (abst) 151, 496
pathology (abst) 485, 490
pathophysiology (abst) 411, 450
physiology (abst) 451. 498, 502
regulation (abst) . . . 154, 168, 178, 178, 303, 324, 454, 457,
462
Cobra venom (abst) 355
Cocaine (abst) 225




basement membrane in the kidney 1195
biosynthesis (abst) 322, 348, 349, 360, 429, 436
glomerular localization 1203





pathophysiology (abst) 216, 383
physiology (abst) 165, 431, 448, 497
transport 450, 451, 482, 484, 489, 501
ultrastructure (abst) 150, 400, 419, 453, 464, 465, 503
Colon neoplasms (abst) 247
Colony stimulating factors (abst) 342, 355, 367
Complement
activation (abst) 258, 308, 365. 372
adverse effects (abst) 353, 355, 363
antagonists and inhibitors (abst) 373
C3 fragments, hemodialysis membranes 576
deficiency (abst) 210, 372
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diagnostic use (abst) 369
induction of IL-i during dialysis 1212
kinetics (abst) 250
pathophysiology (abst) 368
physiology (abst) 242, 248, 256, 266, 268, 341, 362
secretion (abst) 240
Computers (abst) 226, 259, 467
Concanavalins (abst) 164, 354, 360
Concentrating ability (abst) 493
Concentrating capacity in PKD 675
Confocal microscopy (abst) 186, 188
Congestive heart failure (abst) 230, 258, 283, 287
Connecting tubules (abst) 393
Contrast media (abst) 231, 412





currents associated from Na/glucose (abst) 151
Coulter counter (abst) 222
Creatinine
(abst) 200, 231, 526
clearance (abst) 197, 222
Crescentic glomerulonephritis in Natal (abst) 914
Crescents
formation in IgAN (abst) 743
formation in RPGN, autoimmunity 929
Cross infection (abst) 242, 253
Cryoglobulinemia 1004
Crystal growth inhibitor (abst) 363
Cyanate (abst) 196
Cyclic AMP
antagonists and inhibitors (abst) 176
biosynthesis (abst) 318
intracellular (abst) 155, 293, 295
metabolism (abst) 162, 178
pharmacologic actions (abst) 172, 180
physiology (abst) 310, 381, 432









(abst) 207, 210, 211, 346
interstitial nephritis 1257
Cyclosporin A
actions on cultured mesangial cells 632
limits PGE2 formation 1161
steroid-insensitive nephrotic syndrome 909
transplantation and antibody development after
transfusion 1057
Cyclosporine
administration and dosage (abst) 213
adverse effects (abst) . . . 181, 331, 336, 407, 504, 506, 508,
510, 511, 519, 525
analogs and derivatives (abst) 505
dopamine reverses toxicity (abst) 754
drug therapy (abst) 342
hemodynamics in CsA nephrotoxicity,
uninephrectomy 1175
induced hypertension (abst) 748
nephropathy (abst) 407
pharmacokinetics (abst) 510, 513, 514, 516, 517
pharmacologic actions (abst) 402, 476, 507
physiology (abst) 508
therapeutic use (abst) 348, 366, 512, 518, 520
toxicity (abst) . 197, 357, 401, 404, 405, 409, 413, 447, 504,
505, 507, 508, 509, 516, 519, 521, 524, 741
toxicity in microvascular endothelial cells 604
Cystic renal disorders
diagnosis (abst)









Cystine stone formation, MGN
Cystinosis (abst)
Cystinuria, dietary sodium reduction (abst)
Cysts
cell proliferation, fluid secretion 1384
derived cells, no accelerated growth or features in
vitro 1356
formation, tubular basement membrane change 1034
methylprednisolone induced (abst) 747
Cytochalasian B
binding to basolateral membranes 1290
Cytochrome P450 (abst) 290, 295, 312, 426
Cytokine
TNF production, bacterial lipopolysaccharide 1111
vascular indothelium, injury 969
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